Skip to Content
Biotechnology

FDA halts one of the first human CRISPR studies before it begins

A trial planning to use the gene-editing tool CRISPR on sickle-cell patients has been put on hold because of unspecified questions from US regulators.

Background: CRISPR Therapeutics, which is developing the therapy, sought approval from the US Food and Drug Administration in April to begin the study. The therapy involves extracting stem cells from a patient’s bone marrow and editing them with CRISPR in the lab. The idea is that the edited cells, once infused back into the patient, would give rise to healthy red blood cells.

FDA hold: But according to a statement on Wednesday from CRISPR Therapeutics, the FDA ordered the company not to proceed with its study until it answers questions about its treatment (the company didn’t provide any further details about what those questions are, however).

The FDA did not immediately respond to a request for comment.

Planned trials: CRISPR Therapeutics says a European trial for the inherited blood disorder beta thalassemia, which involves a similar procedure, won’t be affected by the FDA’s order. The company plans to begin that study in the second half of the year.

Separately, the first CRISPR trial in the US, conducted by the University of Pennsylvania, is currently enrolling patients.

Deep Dive

Biotechnology

These scientists used CRISPR to put an alligator gene into catfish

The resulting fish appear to be more resistant to disease and could improve commercial production—should they ever be approved.

Next up for CRISPR: Gene editing for the masses?

Last year, Verve Therapeutics started the first human trial of a CRISPR treatment that could benefit most people—a signal that gene editing may be ready to go mainstream.

CRISPR for high cholesterol: 10 Breakthrough Technologies 2023

New forms of the gene-editing tool could enable treatments for common diseases.

An ALS patient set a record for communicating via a brain implant: 62 words per minute

Brain interfaces could let paralyzed people speak at almost normal speeds.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.